Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

Lucio Crinò, Giulio Metro, Lucio Crinò, Giulio Metro

Abstract

There is a major unmet medical need for effective and well-tolerated treatment options for patients with advanced nonsmall cell lung cancer (NSCLC), in both first-line and relapsed/refractory settings. Experimental evidence has validated signalling pathways that regulate tumour angiogenesis, including the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) pathways, as valid anti-cancer drug targets. However, to date, bevacizumab (an anti-VEGF monoclonal antibody) is the only antiangiogenic agent to be approved for the treatment of NSCLC. Many other agents, including antibodies, small-molecule tyrosine kinase inhibitors and vascular disrupting agents, have been assessed in phase III trials but have generally failed to demonstrate clinically meaningful benefits. This lack of success probably reflects the redundancy of proangiogenic pathways and the molecular and clinical heterogeneity of NSCLC. In this review we summarise recently completed and ongoing randomised clinical trials of emerging antiangiogenic agents in patients with NSCLC. We highlight recent promising data with agents that simultaneously inhibit multiple proangiogenic pathways, including the PDGF and FGF pathways, as well as the VEGF pathway. Finally, we discuss the outlook for antiangiogenic agents in NSCLC, emphasising the need for clinically validated prognostic and predictive biomarkers to identify patients most likely to respond to therapy.

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1.
Figure 1.
Molecular pathways underlying angiogenesis. A: Tumour cells produce vascular endothelial growth factor (VEGF)-A and other angiogenic factors, such as basic fibroblast growth factor (bFGF), angiopoietins, interleukin-8, placental growth factor and VEGF-C. These stimulate resident endothelial cells to proliferate and migrate. B: An additional source of angiogenic factors is the stroma. This is a heterogeneous compartment, comprising fibroblastic, inflammatory and immune cells. Recent studies indicate that tumour-associated fibroblasts produce chemokines, such as stromal cell-derived factor (SDF)-1, which may recruit bone-marrow-derived angiogenic cells (BMC). VEGF-A or placental growth factor may also recruit BMC. Tumour cells may also release stromal cell-recruitment factors, such as platelet-derived growth factor (PDGF)-A, PDGF-C or transforming growth factor (TGF)-β. A well-established function of tumour-associated fibroblasts is the production of growth/survival factor for tumour cells, such as epidermal growth factor (EGF) receptor ligands, hepatocyte growth factor and heregulin. C: Endothelial cells produce PDGF-B, which promotes recruitment of pericytes in the microvasculature after activation of PDGF receptor-β. HGF: hepatocyte growth factor. Reproduced from [10] with permission.

References

    1. American Cancer Society. Non-small cell lung cancer survival rates by stage. Date last updated: July 12, 2013. Date last accessed: October 2013.
    1. Peters S, Adjei AA, Gridelli C, et al. . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: Suppl. 7, vii56 vii64.
    1. Sculier JP, Moro-Sibilot D. First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 2009; 33: 915–930.
    1. Oxnard GR, Arcila ME, Chmielecki J, et al. . New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530–5537.
    1. Shepherd FA, Dancey J, Ramlau R, et al. . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.
    1. Hanna N, Shepherd FA, Fossella FV, et al. . Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–1597.
    1. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–132.
    1. Hensing TA, Schell MJ, Lee JH, et al. . Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer 2005; 47: 253–259.
    1. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012; 13: 247–263.
    1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974.
    1. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8: 393–404.
    1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–1027.
    1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714–727.
    1. Sandler A, Gray R, Perry MC, et al. . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550.
    1. Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011; 4: 43–58.
    1. Presta M, Dell’Era P, Mitola S, et al. . Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159–178.
    1. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18: 1855–1862.
    1. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004; 15: 229–235.
    1. Beitz JG, Kim IS, Calabresi P, et al. . Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci USA 1991; 88: 2021–2025.
    1. Wu E, Palmer N, Tian Z, et al. . Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008; 3: e3794.
    1. Reck M, von Pawel J, Zatloukal P, et al. . Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227–1234.
    1. Reck M, von Pawel J, Zatloukal P, et al. . Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804–1809.
    1. Goss GD, Arnold A, Shepherd FA, et al. . Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28: 49–55.
    1. Laurie SA, Solomon BJ, Seymour L, et al. . A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. J Clin Oncol 2012; 30: Suppl. 15, 7511.
    1. Scagliotti G, Novello S, von Pawel J, et al. . Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835–1842.
    1. Paz-Ares LG, Biesma B, Heigener D, et al. . Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30: 3084–3092.
    1. Scagliotti GV, Vynnychenko I, Park K, et al. . International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012; 30: 2829–2836.
    1. Lara PN, Jr, Douillard JY, Nakagawa K, et al. . Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2965–2971.
    1. Ramalingam SS, Dahlberg SE, Langer CJ, et al. . Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26: 60–65.
    1. Leighl NB, Zatloukal P, Mezger J, et al. . Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010; 5: 1970–1976.
    1. Hapani S, Sher A, Chu D, et al. . Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010; 79: 27–38.
    1. Crino L, Dansin E, Garrido P, et al. . Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733–740.
    1. Dahlberg SE, Ramalingam SS, Belani CP, et al. . A. randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). J Clin Oncol 2011; 29: Suppl. 15, TPS218.
    1. Gridelli C, Bennouna J, de Castro J, et al. . Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 2011; 12: 407–411.
    1. Wakelee HA, Dahlberg SE, Keller SM, et al. . Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29: Suppl. 15, 7013.
    1. Wedge SR, Kendrew J, Hennequin LF, et al. . AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389–4400.
    1. Wilhelm SM, Carter C, Tang L, et al. . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109.
    1. Polverino A, Coxon A, Starnes C, et al. . AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66: 8715–8721.
    1. Rugo HS, Herbst RS, Liu G, et al. . Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474–5483.
    1. Schiller JH, Larson T, Ou SH, et al. . Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27: 3836–3841.
    1. Twelves CJ, Chmielowska E, Havel L, et al. . Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol 2014; 25: 132–138.
    1. Pfizer. Evaluation of the efficacy of the combination of axitinib with pemetrexed and cisplatin in the treatment of non-squamous non-small cell lung cancer. NCT00768755. Date last updated: March 28, 2013. Date last accessed: November 11, 2013.
    1. Baguley BC, Siemann DW. Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs 2010; 19: 1413–1425.
    1. Reck M, Kaiser R, Mellemgaard A, et al. . Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: results of Lume-Lung 1, a randomized, double-blind, phase III trial. J Clin Oncol 2013; 31: LBA8011.
    1. Hanna NH, Kaiser R, Sullivan RN, et al. . Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31: 8034.
    1. Herbst RS, Sun Y, Eberhardt WE, et al. . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619–626.
    1. de Boer RH, Arrieta O, Yang CH, et al. . Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067–1074.
    1. Lee JS, Hirsh V, Park K, et al. . Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114–1121.
    1. Natale RB, Thongprasert S, Greco FA, et al. . Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 1059–1066.
    1. Paz-Ares L, Hirsh V, Zhang L, et al. . Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III randomized, double-blind, placebo-controled MISSION trial. Ann Oncol 2012; 23: Suppl. 9, LBA33_PR.
    1. Scagliotti GV, Krzakowski M, Szczesna A, et al. . Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30: 2070–2078.
    1. Herbst RS, Ansari R, Bustin F, et al. . Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1846–1854.
    1. Ramlau R, Gorbunova V, Ciuleanu TE, et al. . Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 2012; 30: 3640–3647.
    1. Hilberg F, Roth GJ, Krssak M, et al. . BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774–4782.
    1. Kutluk Cenik B, Ostapoff KT, Gerber DE, et al. . BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 2013; 12: 992–1001.
    1. Ellis PM, Kaiser R, Zhao Y, et al. . Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010; 16: 2881–2889.
    1. Doebele RC, Conkling P, Traynor AM, et al. . A phase I open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 2094–2102.
    1. Reck M, Kaiser R, Eschbach C, et al. . A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 1374–1381.
    1. Wedge SR, Ogilvie DJ, Dukes M, et al. . ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–4655.
    1. Molina JR, Dy GK, Foster NR, et al. . A. randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol 2011; 29: 7513.
    1. Sun L, Liang C, Shirazian S, et al. . Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116–1119.
    1. Heist RS, Wang XF, Hodgson L, et al. . CALGB 30704: a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: Suppl. 15, 7513.
    1. Novartis International AG. Press release: Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development. Date last updated: November 11, 2010. Date last accessed: November 11, 2013.
    1. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010; 6: 1085–1094.
    1. Camidge DR, Ballas MS, Dubey S, et al. . A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: Suppl. 15, 7588.
    1. Eli Lilly and Co. A study of pemetrexed and carboplatin/cisplatin or gemcitabine and carboplatin/cisplatin with or without IMC-1121B in patients previously untreated with recurrent or advanced non-small cell lung cancer (NSCLC). NCT01160744. . Date last updated: December 17, 2013. Date last accessed: November 11, 2013.
    1. Garon EB, Cao D, Alexandris E, et al. . A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer 2012; 13: 505–509.
    1. Gadgeel SM, Ruckdeschel JC, Wozniak AJ, et al. . Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29: Suppl. 15, 7564.
    1. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008; 9: 1324–1335.
    1. Loyola University. Stage IIIB/IV non-small cell lung cancer. NCT01179269. . Date last updated: October 29, 2012. Date last accessed: November 11, 2013.
    1. UNC Lineberger Comprehensive Cancer Center. Pazopanib in stage IIIB/IV NSCLC lung cancer after progression on first line therapy containing bevacizumab (LCCC0921). NCT01107652. . Date last updated: March 4, 2013. Date last accessed: November 11, 2013.
    1. GlaxoSmithKline. A study to evaluate pazopanib in comparison to pemetrexed in maintenance setting in non-progressing subjects with metastatic stage IVA and IVB non-squamous non-small cell lung cancer (NSCLC) population. NCT01313663. . Date last updated: October 4, 2013. Date last accessed: November 11, 2013.
    1. Infante JR, Novello S, Ma WW, et al. . Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs 2013; 31: 927–936.
    1. Altorki N, Lane ME, Bauer T, et al. . Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010; 28: 3131–3137.
    1. Shankar DB, Li J, Tapang P, et al. . ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007; 109: 3400–3408.
    1. Tan EH, Goss GD, Salgia R, et al. . Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 1418–1425.
    1. Ramalingam SS, Shtivelband M, Soo RA, et al. . Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC. J Clin Oncol 2012; 30: 7512.
    1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175–180.
    1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519–525.
    1. Gadgeel SM. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 96–106.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe